Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the “Investors & Media” page of Regeneron’s website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company’s website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com

Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com

Staff

Recent Posts

A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors

Franklin, Tennessee--(Newsfile Corp. - December 23, 2025) - From global stages and scientific breakthroughs to…

2 hours ago

Waters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026

MILFORD, Mass., Dec. 23, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.,…

2 hours ago

NAVER D2SF-Backed Startups Participate in “CES 2026”

Five teams won CES Innovation Awards, including one Best of Innovation Award and three double…

2 hours ago

Next Gen Diagnostics Launches NGD Infection Prevention to Provide Real-Time Transmission Detection

CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Next Gen Diagnostics (NGD) today announced that January…

2 hours ago

Historic $15 Million Gift Fuels Breakthrough Cancer Care at Hartford HealthCare St. Vincent’s Medical Center

The Estate of Neil Mellen Helps Build Destination for Advanced Cancer Care in ConnecticutBRIDGEPORT, Conn., Dec.…

2 hours ago

Patients Turn to AI for Health Research but Remain Cautious of Accuracy and Privacy Risks

New data from Health Union's survey of over 6,000 patients across 49 chronic conditions shows…

2 hours ago